drugset / Trial / NCT06218667
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
NaSequentialOpen-labelTreatment
Summary
The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.
Timeline
- Start
- 2024-01-11
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | 45 mg | Intravenous |
| Subject | Copanlisib | Small molecule | 60 mg | Intravenous |
| Subject | Degarelix | Other / unclassified | 80 mg | Subcutaneous |